-
Product Insights
Endometriosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Endometriosis Clinical Trial Report Overview A total of 812 Endometriosis clinical trials were conducted as of February 2024. The Endometriosis clinical trial report provides a comprehensive understanding of the Endometriosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       Europe ·       Asia-Pacific ·       ...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Biologic For Crohn’s Disease in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Biologic For Crohn's Disease in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Biologic For Crohn's Disease in Crohn's Disease...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Olamkicept in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olamkicept in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olamkicept in Crohn's Disease (Regional Enteritis) Drug Details: olamkicept (TJ-301)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carbetocin LA in Hemorrhage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carbetocin LA in Hemorrhage report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carbetocin LA in Hemorrhage Drug Details: Carbetocin (Pabal, Duratocin, Caritec, FE-992097) is...
-
Product Insights
Ascites – Drugs In Development, 2023
Global Markets Direct’s, ‘Ascites - Drugs In Development, 2023’, provides an overview of the Ascites pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ascites, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pre-Eclampsia – Drugs In Development, 2023
Global Markets Direct’s, ‘Pre-Eclampsia - Drugs In Development, 2023’, provides an overview of the Pre-Eclampsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hemorrhage – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemorrhage - Drugs In Development, 2023’, provides an overview of the Hemorrhage pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Male Infertility – Drugs In Development, 2023
Global Markets Direct’s, ‘Male Infertility - Drugs In Development, 2023’, provides an overview of the Male Infertility pipeline landscape. The report provides comprehensive information on the therapeutics under development for Male Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Bacterial Vaginosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bacterial Vaginosis - Drugs In Development, 2023’, provides an overview of the Bacterial Vaginosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Drugs In Development, 2023’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...